Advancing synoptic cancer reports beyond English: the University of Bern/PathoLink approach.

Synoptic reporting (SR) increases completeness and improves the understanding of pathology reports for tumours as compared to the more traditional “narrative” style. Furthermore, it is an important step towards higher levels of structured data capture [1]. SR is defined by a set of required data elements (RDE) specific for each tumour type and a characteristic paired format of RDE and response. The College of American Pathologists (CAP) requires accredited pathology laboratories to report many cancer types in a synoptic format and for this purpose publishes a comprehensive set of protocols [2]. More recently, the International Collaboration for Cancer Reporting (ICCR)—sponsored amongst others by the European Society of Pathology—has started to publish synoptic protocols with the aim to “produce internationally standardised and evidence-based datasets for the pathology reporting of cance

The multiplicity fraction in 202 open clusters from Gaia

In this study, we estimate the fraction of binaries with high mass ratios for 202 open clusters in the extended solar neighbourhood (closer than 1.5 kpc from the Sun). This is one of the largest homogeneous catalogues of multiplicity fractions in open clusters to date, including the unresolved and total (close-binary) multiplicity fractions of main-sequence systems with mass ratio larger than $0.6_{-0.15}^{+0.05}$. The unresolved multiplicity fractions are estimated applying a flexible mixture model to the observed Gaia colour-magnitude diagrams of the open clusters. Then we use custom Gaia simulations to account for the resolved systems and derive the total multiplicity fractions. The studied open clusters have ages between 6.6 Myr and 3.0 Gyr and total high-mass-ratio multiplicity fractions between 6% and 80%, with a median of 18%. The multiplicity fractions increase with the mass of the primary star, as expected. The average multiplicity fraction per cluster displays an overall decreasing trend with the open cluster age up to ages about 100 Myr, above which the trend increases. Our simulations show that most of this trend is caused by complex selection effects (introduced by the mass dependence of the multiplicity fraction and the magnitude limit of our sample). Furthermore, the multiplicity fraction is not significantly correlated with the clusters' position in the Galaxy. The spread in multiplicity fraction decreases significantly with the number of cluster members (used as a proxy for cluster mass). We also find that the multiplicity fraction decreases with metallicity, in line with recent studies using field stars.Comment: 17 pages, 13 figures, resubmitted to A&A following referee comment

Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study

Objective Two randomized phase III trials demonstrated the efficacy and safety of combining bevacizumab with front-line carboplatin/paclitaxel for advanced ovarian cancer. The OSCAR (NCT01863693) study assessed the impact of front-line bevacizumab-containing therapy on safety and oncologic outcomes in patients with advanced ovarian cancer in the UK. Methods Between May 2013 and April 2015, patients with high-risk stage IIIB–IV advanced ovarian cancer received bevacizumab (7.5 or 15 mg/kg every 3 weeks, typically for ≤12 months, per UK clinical practice) combined with front-line chemotherapy, with bevacizumab continued as maintenance therapy. Co-primary endpoints were progression-free survival and safety (NCI-CTCAE v4.0). Patients were evaluated per standard practice/physician’s discretion. Results A total of 299 patients received bevacizumab-containing therapy. The median age was 64 years (range 31–83); 80 patients (27%) were aged ≥70 years. Surgical interventions were primary debulking in 21%, interval debulking in 36%, and none in 43%. Most patients (93%) received bevacizumab 7.5 mg/kg with carboplatin/paclitaxel. Median duration of bevacizumab was 10.5 months(range <0.1–41.4); bevacizumab and chemotherapy were given in combination for a median of three cycles (range 1–10). Median progression-free survival was 15.4 (95% CI 14.5 to 16.9) months. Subgroup analyses according to prior surgery showed median progression-free survival of 20.8, 16.1, and 13.6 months in patients with primary debulking, interval debulking, and no surgery, respectively. Median progression-free survival was 16.1 vs 14.8 months in patients aged <70 versus ≥70 years, respectively. The 1-year overall survival rate was 94%. Grade 3/4 adverse events occurred in 54% of patients, the most common being hypertension (16%) and neutropenia (5%). Thirty-five patients (12%) discontinued bevacizumab for toxicity (most often for proteinuria (2%)). Conclusions Median progression-free survival in this study was similar to that in the high-risk subgroup of the ICON7 phase III trial. Median progression-free survival was shortest in patients who did not undergo surgery

A functional form for a representative individual arterial input function measured from a population using high temporal resolution DCE MRI

Purpose: To measure the arterial input function (AIF), an essential component of tracer kinetic analysis, in a population of patients using an optimized dynamic contrast-enhanced imaging sequence and to estimate inter- and intra-patient variability. From these data to extract a representative AIF that may be used for realistic simulation studies. Methods: Thirty-nine female patients were imaged on multiple visits before and during a course of neoadjuvant chemotherapy for breast cancer. A total of 97 T1-weighted dynamic contrast-enhanced studies were analyzed including bookend estimates of T1 and model-fitting to each individual AIF. Area under the curve and cardiac output were estimated from each first pass peak and these data were used to assess inter- and intra-patient variability of the AIF. Results: Inter-patient variability exceeded intra-patient variability of the AIF. There was no change in cardiac output as a function of MR visit (mean value 5.6 ± 1.1 L/min) but baseline blood T1 increased significantly following the start of chemotherapy (which was accompanied by a decrease in hematocrit). Conclusion: The AIF in an individual patient can be measured reproducibly but the variability of AIFs between patients suggests that use of a population AIF will decrease the precision of tracer kinetic analysis performed in cross-patient comparison studies. A representative AIF is presented that is typical of the population but retains the characteristics of an individually measured AIF

The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.

Eighty-two patients were randomly allocated to receive intravenous acyclovir 5 mg kg-1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6-hourly for 6 months or matching placebos after allogeneic bone marrow transplantation. Herpes simplex and varicella zoster virus infections were significantly reduced during the period of administration of acyclovir. No reduction in cytomegalovirus infection was demonstrated. The drug was not toxic

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK

Aims: Ovarian cancer is the principal cause of gynaecological cancer death in developed countries, yet overall survival in the UK has been reported as being inferior to that in some Western countries. As there is a range of survival across the UK we hypothesised that in major regional centres, outcomes are equivalent to the best internationally. Materials and methods: Data from patients treated in multicentre international and UK-based trials were obtained from three regional cancer centres in the UK; Manchester, University College London and Leeds (MUL). The median progression-free survival (PFS) and overall survival were calculated for each trial and compared with the published trial data. Normalised median survival values and the respective 95% confidence intervals (ratio of pooled MUL data to trial median survival) were calculated to allow inter-trial survival comparisons. This strategy then allowed a comparison of median survival across the UK, in three regional UK centres and in international centres. Results: The analysis showed that the trial-reported PFS was the same in the UK, in the MUL centres and in international centres for each of the trials included in the study. Overall survival was, however, 45% better in major regional centre-treated patients (95% confidence interval 9–73%) than the median overall survival reported in UK trials, whereas the median overall survival in MUL centres equated with that achieved in international centres. Conclusion: The data suggest that international survival statistics are achieved in UK regional cancer centres

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas

Background: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Current international guidelines do not recommend surgical treatment of liver metastases, however the existing data are scarce. The aim of this study was to evaluate the results of curatively intended resection/radiofrequency ablation (RFA) of liver metastases in patients with metastatic GEP-NEC. Methods: 32 patients with a diagnosis of high-grade gastroenteropancreatic neuroendocrine neoplasm (Ki-67 > 20%) and with intended curative resection/RFA of liver metastases, were identified among 840 patients from two Nordic GEP-NEC registries. Tumor morphology (well vs poor differentiation) was reassessed. Overall survival (OS) and progression-free survival (PFS) was assessed by Kaplan Meier analyses for the entire cohort and for subgroups. Results: Median OS after resection/RFA of liver metastases was 35.9 months (95% -CI: 20.6-51.3) with a five-year OS of 43%. The median PFS was 8.4 months (95% -CI: 3.9-13). Four patients (13%) were disease -free after 5 years. Two patients had well -differentiated morphology (NET G3) and 20 patients (63%) had Ki-67 >= 55%. A Ki-67 <55% and receiving adjuvant chemotherapy were statistically significant factors of improved OS after liver resection/RFA. Conclusion: This study shows a long median and long term survival after liver surgery/RFA for these selected metastatic GEP-NEC patients, particularly for the group with a Ki-67 in the relatively lower G3 range. Our findings indicate a possible role for surgical treatment of liver metastases in the management of this patient population. (C) 2017 Elsevier Ltd, BASO - The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.Peer reviewe

Memoria, responsabilidad, resistencia. Apuntes sobre ética y política en la ficción de José Saramago

Las tres nociones teóricas que constituyen el dispositivo conceptual de la propuesta aquí presentada, que lleva por título: Memoria, responsabilidad, resistencia (apuntes sobre ética y política en la ficción de José Saramago) y que tienen como eje articulador la marginalidad (desde que opera –benjaminianamente – sobre las relaciones de desigualdad y exclusión), orientan el trabajo heurístico con los textos escogidos como corpus y circunscriben sus alcances y limitaciones. Lo que se pretende en esta nueva etapa –entendida como continuidad de un proceso – es construir una teoría de análisis del discurso saramaguiano desde su intelección ético-política , tomando como referenciales las nociones bajtinianas de «discurso, epistemología, antagonismo, ideología, sujeto y poder». Y para ello, el «recorte» procedimental de las categorías enunciadas sirve como línea transversal de lectura que despliega las significaciones narrativas y las transforma en enunciados de valor y toma de posición. «Memoria» entendida en singular recoge las tesis benjaminianas sobre el «concepto de historia» que operan sobre ese radical campo de estudio que es el «pasado» y recuperan las voces acalladas de los «oprimidos» de la historia, postulando una lectura «a contrapelo » de la historia nacional y global. Situándose, en el caso de las referencialidades saramaguianas, en el contexto que articula la dictadura antes y después de su presencia en el escenario del siglo XX, el trabajo analítico focalizará en los modos de perduración de la memoria y la capacidad pregnante de irrumpir en el presente instaurando nuevos modos discursivos de resistencia. La noción de «responsabilidad» tiene una herencia múltiple en el equipo de investigación pero –sobre todo– conjuga con las tesis de Tzvetan Todorov sobre la ética de las víctimas, adentrándose en el estudio de la «alteridad» como presupuesto indiscutible y con el concepto de eticidad, vinculado a la teoría del reconocimiento desarrollada por Axel Honneth. Por último, la «resistencia» abre hacia una lectura política de la ficción de José Saramago que el procedimiento heurístico y hermenéutico de la investigación, a partir de los enunciados de Foucault y de Said –entre otros– pretende radicalizar. La conjunción tripartita de las nociones destacadas y su dinamicidad dialéctica aseguran la constitución de un referencial teórico que pretende instalar en el aparato crítico sobre la ficción del autor portugués, un dispositivo conceptual a partir del cual dialogar con el pensamiento y la filosofía contemporáne

Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects

Pancreatic neuroendocrine neoplasms (PanNENs) are the second most common malignancy of the pancreas. Surgery remains the only curative treatment for localized disease. For patients with inoperable advanced or metastatic disease, few targeted therapies are available, but their efficacy is unpredictable and variable. Exploiting prior knowledge on pathogenetic processes involved in PanNEN tumorigenesis, we tested buparlisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor), as single agents or in combination, in different preclinical models. First, we used cell lines representative of well-differentiated (INS-1E, NT-3) and poorly differentiated (BON-1) PanNENs. The combination of buparlisib with ribociclib reduced the proliferation of 2D and 3D spheroid cultures more potently than the individual drugs. Buparlisib, but not ribociclib, induced apoptosis. The anti-proliferative activity of the drugs correlated with downstream target inhibition at mRNA and protein levels. We then tested the drugs on primary islet microtissues from a genetic PanNET animal model (Men1-defective mice) and from wild-type mice: the drug combination was effective against the former without altering islet cell physiology. Finally, we treated PanNET patient-derived islet-like 3D tumoroids: the combination of buparlisib with ribociclib was effective in three out of four samples. Combined targeting of PI3K and CDK4/6 is a promising strategy for PanNENs spanning various molecular and histo-pathological features

Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects.

Pancreatic neuroendocrine neoplasms (PanNENs) are the second most common malignancy of the pancreas. Surgery remains the only curative treatment for localized disease. For patients with inoperable advanced or metastatic disease, few targeted therapies are available, but their efficacy is unpredictable and variable. Exploiting prior knowledge on pathogenetic processes involved in PanNEN tumorigenesis, we tested buparlisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor), as single agents or in combination, in different preclinical models. First, we used cell lines representative of well-differentiated (INS-1E, NT-3) and poorly differentiated (BON-1) PanNENs. The combination of buparlisib with ribociclib reduced the proliferation of 2D and 3D spheroid cultures more potently than the individual drugs. Buparlisib, but not ribociclib, induced apoptosis. The anti-proliferative activity of the drugs correlated with downstream target inhibition at mRNA and protein levels. We then tested the drugs on primary islet microtissues from a genetic PanNET animal model (Men1-defective mice) and from wild-type mice: the drug combination was effective against the former without altering islet cell physiology. Finally, we treated PanNET patient-derived islet-like 3D tumoroids: the combination of buparlisib with ribociclib was effective in three out of four samples. Combined targeting of PI3K and CDK4/6 is a promising strategy for PanNENs spanning various molecular and histo-pathological features